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CAS CLINIQUE | CASE REPORT

Médecine Orale / Oral Medicine

MALIGNANT MELANOMA OF THE ANTERIOR
MANDIBULAR GINGIVA: A CASE REPORT
Bhandarkar Gowri Pandarinath* | Shetty Kushal**
Abstract
Oral malignant melanoma is an infrequent neoplasm making up less than 1% of all melanomas; its behavior is more aggressive when
compared to melanomas of the skin. We present a rare case of a 50-year-old male patient with a stage II oral malignant melanoma
of the anterior mandibular gingiva treated with surgery and radiotherapy.
Keywords: Oral malignant melanoma - oral pigmentation - mucosal melanoma.
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MÉLANOME MALIN DE LA GENCIVE MANDIBULAIRE ANTÉRIEURE
Résumé
Le mélanome oral malin est une néoplasie rare représentant moins de 1% des mélanomes ; il présente un comportement beaucoup
plus agressif que ceux de la peau. Nous présentons un cas rare de mélanome malin oral de la gencive mandibulaire antérieure chez
un homme de 50 ans, traité par chirurgie et radiothérapie.
Mots-clés: Mélanome oral malin - pigmentation orale - mélanome muqueux.
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Introduction
Melanomas are malignant neoplasms
arising from melanocytes, which originate from the neural crest cells and
produce the melanin pigment of the
epithelium’s basal layer. These neoplasms are grouped under the name of
“Dispersed Neuro-Endocrine System
(DNES) tumors”. Melanomas are present primarily in the basal portion of
the epidermis at the dermal-epidermal
junction [1].
Over 90% of melanomas occur on the
skin with slightly more than 1% arising
from mucosal surfaces [2]. The sites
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of predilection for mucosal malignant
melanomas are commonly the rectum
and the vulvo-vaginal regions. In the
head and neck region, nasal and paranasal melanomas are three times more
common than oral malignant melanomas (OMM) [3]. These latter have
a much poorer prognosis than those
developing on the skin [4]. Primary
OMMs are rare, representing 0.2–8% of
all melanomas [5] and accounting for
0.5% of all oral malignancies [6].

Case report
A 50-year-old male patient presented
to our department with an asymptomatic pigmented lesion discovered on the
mandibular gingiva nine months ago.
Initially the patient had noticed the
change in the color of the vestibular
gums. Three months later, he noticed a
swelling in the same region and stated
that the adjacent teeth had become
mobile with the swelling gradually
increasing in size.
Patient’s medical history was noncontributory. Thorough anamnesis
and physical examination ruled out
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the possibility of melanotic lesions
elsewhere in the body; the oral lesions
were considered “primary”. On extraoral examination, submandibular lymphnodes were palpable on right and
left sides. They were non-tender, about
1 cm in size, firm and freely mobile.
Intraoral examination showed a fungated, pigmented mass, measuring
about 4×2.5cm on the labial gingiva
extending to the lingual aspect of the
anterior mandibular region (Fig. 1). It
extended from the lower left lateral
incisor region to that of the lower right
canine, crossing the midline. Its surface was lobulated with a purplish-red
discoloration of the overlying mucosa.
Its consistency was non-tender and
firm.
The dental panoramic x-ray revealed
soft tissue shadow of the mass with
bone loss extending from the region
of the lower left central incisor to the
lower right premolar. There was also
loss of the lamina dura in relation to
the lower left anterior quadrant, with
migration of the left lateral incisor
laterally whereas the left central incisor exhibited a floating tooth appearance [Fig.2].
Considering the history, the clinical
examination and the radiological findings, malignant melanoma was the
provisional diagnosis. Differential diagnosis of Kaposi’s sarcoma, giant cell
lesion and pyogenic granuloma were
advocated. Based on clinical staging
system for primary OMM, the present
case was classified under stage II [7].
The routine blood and biochemical
investigations were found to be within
normal limits and the patient was nonreactive for HIV 1 and 2. Chest x-ray
revealed no abnormality. Ultrasound of
the abdomen ruled out liver metastasis. Incisional biopsy of the pigmented
mass was done and histopathological
findings were suggestive of malignant
melanoma [Fig.3].
The surgical treatment consisted
of marginal mandibulectomy and
bilateral radical neck dissection.
Histopathological examinations of

the resected material showed malignant melanoma of the gingiva invading the mandibular bone. The patient
was treated with radiotherapy to the
tumoral and neck region. Patient is
symptom-free for about a year now of
follow-up.

Discussion
Oral malignant melanoma is a rare
aggressive neoplasm of the melanocytes, located along the tips and
peripheries of the rete pegs. The ratio
of melanocytes to keratinocytes in
gingiva is 1:15 [3]. Melanocytes differ from nevus cells and melanoma
cells in showing features of pleomorphism, hyperchromatism, prominent
nucleoli and mitotic activity [3].
In contrast to cutaneous melanomas etiologically linked to sun exposure, mucosal melanomas can occur
either owing to certain risk factors,
like tobacco use and chronic irritation, or may be de novo [6]. Some
may arise from pre-existing nevi,
especially atypical (dysplastic) nevi,
and congenital hairy nevi [8]. Genes
implicated in the development of
melanomas include CDKN2A (p16),
CDK4 (chromosome 12q15), RB1,
CDKN2A (p19) and PTEN/MMAC1 [9].
OMM generally affects in adults
between 55 and 65 years of age [10]
and more commonly among the
Japanese with a male to female ratio of
almost 2:1. It often occurs in the hard
palate and the maxillary gingiva [11].
As the palate is continuously exposed
to the air while breathing, irritants
and carcinogenic compounds in the
air (such as components of tobacco
smoke) may play a contributing role in
the development of melanomas [10]. It
is interesting that among pigmented
lesions of the oral cavity, oral nevomelanocytic nevi (OMNs) are localized
mostly in the palate and this finding
may lead to the hypothesis that subtypes of OMNs could be precursors of
the pathogenesis of OMM [12]. Less
commonly, melanomas also affect lips,
buccal mucosa, mandibular gingiva,

tongue and floor of the mouth [4].
Our case report of OMM with respect
to mandibular gingiva can therefore
be regarded as a rare case seen in a
male patient at the mandibular arch.
According to Tanaka et al. [13], oral
melanomas could be classified into
five types based on their clinical
appearance: pigmented nodular, nonpigmented nodular, pigmented macular, pigmented mixed and non-pigmented mixed. The clinical coloration
can appear as black, grey, purple or
even reddish. The tumors are asymmetric, irregular in outline and occasionally multiple. Pain, ulceration
and bleeding are rare until late stages
of the disease. Lopez- Graniel et al.
[14] stated that haemorrhage was the
most common presenting symptom.
Rolled borders are not a feature of oral
mucosa melanoma because the atypical melanocytes exhibit a pagetoid
mode of spread resulting in a uniform
epithelial thickening [15]. No induration is observed which may be explained by the small, if not totally absent,
inflammatory cell response at the lateral edges of the vertical growth phase
[16]. In our case report, the patient
presented with a pigmented, purplishred, non-tender and non-indurated
mass.
Adjunctive
radiologic
diagnostic
methods such as computed tomography, magnetic resonance imaging
and positron emission tomography
(staging purposes) are sometimes
useful [7] and should be undertaken
to explore regional metastases to the
submandibular and cervical nodes.
Incisional biopsy is the method of
choice for diagnosis [17].
An incisional biopsy was performed
in our case, suggestive of OMM of the
mandibular anterior gingiva.
Greene et al. [18] proposed three criteria for the diagnosis of primary OMM:
1) demonstration of malignant melanoma of the oral mucosa, 2) presence
of so-called junctional activity (i.e. the
melanocytes are arranged along the
basal layer of the surface epithelium) in
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Fig. 1: Pigmented mass on anterior
mandibular gingiva.

Fig. 2: The orthopantomogram revealed loss of the lamina dura
in relation to the lower anterior quadrant, with migration of 32
laterally; the 31 exhibited a floating tooth appearance.

the lesion, and 3) the inability to show
malignant melanoma in any other primary site. Based on these criteria, our
case was diagnosed as primary OMM.
Clinical staging system for primary
oral melanoma with histopathological
microstaging is as follows [7]:
Stage I: Primary tumor present only
(N0M0).
Level I: Pure in situ melanoma without
evidence of invasion or in situ melanoma with microinvasion.
Level II: Invasion up to the lamina
propria.
Level III: Deep tissue invasion into the
skeletal muscle, bone or cartilage.
Stage II: Tumor metastatic to regional
lymph nodes (T any N1M0).
Stage III: Tumor metastatic to distant
sites (T any M1). Some authors reported a survival rate of 30% in tumors
having a thickness of <5 mm, dropping to 18% in tumors with >5 mm
thickness, and to 10% in patients with
tumor thickness >1 cm [19]. Based
on this, our case would belong to the
group of patients having 10% survival
rate as the tumor thickness is more
than 1 cm.
The mainstay of treatment is wide
surgical resection aiming at complete
resection of the primary tumor and any
positive cervical lymph nodes.
A sentinel lymphnode is the first
lymphnode(s) to which cancer cells are
most likely to spread from a primary
tumor [20]. A sentinel lymphnode biopsy (SLNB) can be used to help deter-

mine the extent or stage of cancer in
the body. Because SLNBs involve less
extensive surgery and the removal
of fewer lymph nodes than standard
lymphnode surgery, the potential for
adverse effects or harms is lower.
A negative SLNB result suggests that
cancer has not acquired yet the ability
to spread to nearby lymphnodes or
other organs. A positive SLNB result
indicates that cancer had reached
the sentinel lymphnode and may be
present in other nearby lymphnodes
(called regional lymphnodes) and possibly, other organs. This information
can help determining the stage of the
cancer (extent of the disease within the
body) and developing an appropriate
treatment plan.
SLNBs may be done on an outpatient
basis or may require a short stay in the
hospital. In addition to helping doctors
stage cancers and estimate the risk
of spread to other parts of the body,
SLNB may help some patients avoid
more extensive lymphnode surgery.
Removing additional nearby lymph
nodes to look for cancer cells may
not be necessary if the sentinel node
is negative for cancer. All lymphnode
surgery can have adverse effects and
some of these effects may be reduced
or avoided if fewer lymphnodes are
removed. The potential adverse effects
of lymphnode surgery include the
following:
- Lymphedema or tissue swelling.

- Seroma or the buildup of lymph fluid
at the site of the surgery.
- Numbness, tingling, or pain at the
site of the surgery.
- Difficulty moving the affected body
part.
SLNB like other surgical procedures
can cause short-term pain, swelling,
and bruising at the surgical site and
can increase the risk of infection. In
addition, some patients may have
skin or allergic reactions to the blue
dye used in SLNB. Another potential
harm is a false-negative biopsy result
which gives the patient and the doctor a false sense of security about the
extent of cancer in the patient’s body.
Researchers have investigated whether
patients with melanoma whose sentinel lymphnode is negative for cancer
and who have no clinical signs of other
lymph node involvement can also be
spared more extensive lymphnode
surgery at the time of primary tumor
removal [20].
Sentinel-node biopsy or lymphoscintigraphy, beneficial in staging of cutaneous melanomas, has less value in
staging or treating oral melanomas.
Complex and ambiguous drainage patterns may result in the bypass of some
first-order nodes and in the occurrence
of metastasis in contralateral nodes
[21].
Amelanotic melanomas can resemble
many different mesenchymal neoplasms, and immunohistochemical
stains must be used for diagnosis. The
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Fig. 3: Haematoxyllin and Eosin sections revealed numerous atypical melanocytes within
the epithelium and invasion into the connective tissue. These cells are epitheloid to
spindle in shape, with vesicular, hyperchromatic nuclei and prominent nucleoli.

pathologist should look for evidence
of a lymphocytic reaction within the
connective tissue and an increased
number of melanocytes in the basal
cell layer as an indication for immunohistochemical staining.
Leukocyte common antigen and Ki-1
are used to identify the lymphocytic
lesions. Cytokeratin markers, often
cocktails of high– and low–molecular-weight cytokeratins, can be
used to help identifying epithelial
malignancies.
The positivity to S-100 protein and
homatropine methylbromide antigen (HMB-45) is characteristic of,
although not specific for melanomas.
S-100 protein is frequently used to
highlight the spindled, more neural-appearing melanocytes whereas
HMB-45 is used to identify round cells.
Immunohistochemical tests revealed
that there was intense and widespread
positivity for NKFC3- associated melanoma antigens and focal positivity for
vimentin and cytokeratin. Melanomas,
unlike epithelial lesions, are identified
by using vimentin, a marker of mesenchymal cells.

Microphthalmic-associated transcription factor (MITF), tyrosinase, and
melanoma antigen (Melan-A) immunostains have been used to highlight
melanocytes. The inclusion of these
stains in a panel of stains for melanoma may be beneficial [2]. The use
of at least 2 different immunostains is
recommended for diagnosis.
MITF has value in decorating amelanotic melanomas and desmoplastic
melanomas when other immunohistochemical stains have failed. S-100 protein and tyrosinase show the highest
percentage of positivity. MART-1/
Melan-A is reported to be much more
useful than HMB-45 for highlighting
melanocytic tumors, but because it
is a marker of melanocyte lineage,
benign lesions such as melanocytic
nevi also stain [21]. Reddy et al. in
their case showed that special stains
like Masson’s Fontana silver stain and
Melanin Bleach technique are also
helpful in the diagnosis of malignant
melanoma for which they were positive [22].
Although melanoma is classically not
radiosensitive, occasional patients
have shown a good response to radia-

tion therapy. Immunotherapy has been
successfully used but chemotherapy
has demonstrated a relatively low response rate. Dacarbazine-DTIC, INF-γ
and INF-α-2b have been described
as chemotherapeutical and immunotherapeutical treatments associated
with Bacillus-Calmette-Guerin vaccine
and recombinant interleukin-2 (rIL-2)
in different combinations. Anecdotal
reports describe success with IFN-α
or hyperfractionated radiation therapy. Many cancer centers follow surgical excision with a course of IL-2 as
adjunctive therapy to prevent or limit
recurrence. Peginterferon alpha-2b
(Sylatron™) has been approved by the
FDA for melanomas with microscopic
or gross nodal involvement within 84
days of definitive surgical resection
including complete lymphadenectomy.
Clinical trials of ipilimumab, a human
monoclonal antibody, have shown
encouraging results in therapy for
metastatic melanoma. The drug blocks
regulation of cytotoxic T-lymphocytes
and allows sustained immunologic activity against melanomas and
other malignancies. Ipilimumab body
(Yervoy™) is now approved by the US
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Food and Drug Administration (FDA)
and is indicated for unresectable or
metastatic melanomas [21].
The protocol of immunochemotherapy
includes DTC (dimethyltriazeno-imidazole-carboxamide), ACNU (nimustine
hydrochloride) and VCR (vincristine)
which is also known as DAV protocol
[23], coupled with OK-432 which is a
biologic response modifier consisting
of penicillin treated Streptococcus
pyogenes and INF -α2.
Other immunotherapeutic drugs that
are occasionally used include interferon and cimetidine, which, when used
together, are believed to activate killer
T cells and inhibit suppressor T cells,
resulting in reduction of the size of the
melanoma.
For patients with evidence of multiple
positive lymphnodes or with extracapsular spread, post-operative radiation
therapy after neck dissection seems
to be appropriate [2]. In our case also,
patient was treated by radiotherapy
post-operatively. Radiation can also be
used palliatively for metastatic disease
[2]. Although radiation alone is reported to have questionable benefit (particularly in small fractionated doses),
this therapy is a valuable adjuvant in
achieving relapse-free survival when
high-fractionated doses are used [21].
The melanoma-associated antigen
(MAGE) family consists of a number
of antigens initially recognized by
cytotoxic T lymphocytes, which are
currently being investigated for immunotherapy of patients with metastatic
melanomas and other tumor types.
Expression of MAGE mRNA in melanocytic tumors is said to be restricted to
invasive malignant tumors and absent
in nevi. Recently, a monoclonal antibody (57B) has become available to
examine MAGE protein expression in
archival material. Because tumor-infiltrating lymphocytes in melanomas are
associated with longer survival, their
findings suggested a potential prognostic role for MAGE. Furthermore,
the seeming restriction of immunopositivity to invasive malignant tumors

suggests a potential diagnostic role
for the antibody 57B in confirming the
malignant potential of a melanocytic
tumor [24].
One reason for the poor prognosis of
OMM is early invasion of the underlying tissue, increasing the likelihood
of metastasis [13]. The five-year survival rate for OMM ranges from 9.4–
15.6% even after radical treatment.
It depends on whether there is lymphnode involvement (18 months) or
not (46 months) [6] and worsens with
distant metastasis. The most common
sites of metastasis are lymphnodes,
liver and lung with widespread involvement occurring in severe cases.

Conclusion
The present case emphasizes the
importance of early diagnosis and
management which could improve the
survival rate in patients with OMM.
In our case, one year survey speaks
about and weighs little the importance
of patient counseling. Educating and
motivating the patients for follow-up
play a very important role in increasing
his/her life span and must be stressed
upon to the patient.
Early identification of oral melanomas
should be promoted by careful oral
examination and early biopsy of pigmented and non-pigmented suspected masses since early diagnosis and
intervention results in better prognosis [22].
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